Trial-Results center  
Clinical trial results database in 100 Feedback    Home


Related trials

Buse, 2011 - exenatide vs placebo add on insulin

Lewin, 2010 - linagliptin vs placebo (add on to sulphonylurea)

DURATION-2 (Bergenstal) (vs sitagliptin), 2010 - exenatide vs sitagliptin

DURATION-3 (Diamant), 2010 - exenatide vs insulin glargine

Ratner DRI6012, 2010 - lixisenatide vs placebo add on MET

DURATION-2 (Bergenstal) (vs pioglitazone), 2010 - exenatide vs pioglitazone

Goodman, 2009 - vildagliptin vs placebo (add on to metformin)

HOME, 2009 - metformin vs placebo

LEAD-2 (Nauck) (vs placebo), 2009 - liraglutide vs placebo add on MET

Nauck (Sulf vs pbo), 2009 - vs placebo

9607, 2009 - exenatide vs placebo add on MET+/-SU

Li, 2009 - nateglinide vs repaglinide

LEAD-2 (vs MET), 2009 - liraglutide vs metformin

Ferrannini, 2009 - vildagliptin vs Sulfonylurea (add on to metformin)

LEAD-3 mono (Garber), 2009 - liraglutide vs glimepiride

Kaku, 2009 - mitiglinide vs placebo (on top pioglitazone )

COSMIC, 2009 - vs

LEAD-2 (Nauck) (vs glimepiride), 2009 - liraglutide vs glimepiride add on MET

DeFronzo, 2009 - saxagliptin vs placebo (add on to metformin)

RECORD, 2009 - rosiglitazone vs standard glucose-lowering drugs

Nauck, 2009 - alogliptin vs placebo (add on to metformin)

Nauck (vs GLP-1 analog), 2009 - vs GLP-1 analog

Filozof, 2009 - vildagliptin as add-on therapy vs gliclazide

Bolli, 2008 - vildagliptin vs pioglitazone (on top of metformin)

Moretto, 2008 - exenatide vs placebo



See also:

  • All test diabète clinical trials
  • All diabetes clinical trials
  • All type 2 diabetes - sanofi clinical trials
  • All clinical trials of insulin secretagogues peptides (incretins)
  • All clinical trials of liraglutide
    		•  

    Madsbad (vs Glimepiride) study, 2004

    download pdf: liraglutide | insulin secretagogues peptides (incretins) for diabetes

    Treatments

    Studied treatment Liraglutide 0.045–0.75 mg daily
    Control treatment Glimepiride
    Concomittant treatment None

    Patients

    Baseline characteristics
    Age (year) 57  
    Duration of diabetes (year) 4.5 y 
    HbA1c (%) 7.5 
    BMI 30.4 
    Add-on to None 

    Method and design

    Randomized effectives 135 / 26 (studied vs. control)
    Blinding open
    Follow-up duration 12 weeks


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    severe hypoglycemia

    0 / 135
         0 / 26
         classic 0,19 [0,00;48,45]

    diarrhoea

    5 / 135
         0 / 26
         classic 4,04 [0,07;218,67]

    All cause death

    0 / 135
         0 / 26
         classic 0,19 [0,00;48,45]

    all hypoglycemia

    1 / 135
         4 / 26
         0,05 [0,01;0,41]

    vomiting

    3 / 135
         1 / 26
         classic 0,58 [0,06;5,34]

    cardiovascular events

    0 / 135
         0 / 26
         classic 0,19 [0,00;48,45]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    severe hypoglycemia 0 / 135 (0,4%) 0 / 26 (1,9%) 0,19 [0,00;9,49] 12053
    vomiting 3 / 135 (2,2%) 1 / 26 (3,8%) 0,58 [0,06;5,34] 12053
    cardiovascular events 0 / 135 (0,4%) 0 / 26 (1,9%) 0,19 [0,00;9,49] 12053
    all hypoglycemia 1 / 135 (0,7%) 4 / 26 (15,4%) 0,05 [0,01;0,41] 12053
    diarrhoea 5 / 135 (3,7%) 0 / 26 (1,9%) 1,93 [0,11;34,20] 12053
    All cause death 0 / 135 (0,4%) 0 / 26 (1,9%) 0,19 [0,00;9,49] 12053
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 12053: Monami M, Marchionni N, Mannucci EGlucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.Eur J Endocrinol 2009;160:909-17

    • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    vomiting 2,22% 3,85% -16,2‰
    all hypoglycemia 7,41‰ 15,38% -146,4‰

    Meta-analysis of all similar trials:

    antidiabetic drugs in test diabète for type 2 daibetes (NIDD)

    insulin secretagogues peptides (incretins) in diabetes for all type of patients

    insulin secretagogues peptides (incretins) in type 2 diabetes - sanofi for all type of patients



    Reference(s)

    Trials register # NA
    • Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.. Diabetes Care 2004;27:1335-42
      Pubmed | Hubmed | Fulltext

    (c) 2004-2011 TrialResults-center - All Rights Reserved

    Tweet this  |  Facebook  |  notify a friend